Osteopore Secures Additional Funding Through Further Convertible Note Drawdown
Osteopore Limited (ASX: OSX) has completed a further drawdown under the second tranche of its existing redeemable convertible note facility, strengthening its funding position as it continues to advance commercial and development initiatives. The Company confirmed that Advance Opportunities Fund and Advance Opportunities Fund I have subscribed for an additional AU$250,000 sub-tranche under Tranche 2 of the facility. The latest drawdown relates to Sub-Tranche 04 (ST04) and follows previous subscriptions totalling AU$750,000 under Tranche 2 earlier in 2026. The broader funding agreement provides for up to AU$20 million in 4.0% redeemable convertible notes, structured across four tranches of AU$5 million each. Management stated that proceeds from the latest subscription will support ordinary business activities as well as future development programs, projects and investment opportunities as they arise. The additional funding provides Osteopore with increased financial flexibility as it continues commercialising its portfolio of 3D-printed biomimetic and bioresorbable implants within the regenerative medicine sector.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Osteopore Secures Additional Funding Through Further Convertible Note Drawdown
Osteopore Limited (ASX: OSX) has completed a further drawdown under the second tranche of its existing redeemable convertible note facility, strengthening its funding position as it continues to advance commercial and development initiatives. The Company confirmed that Advance Opportunities Fund and Advance Opportunities Fund I have subscribed for an additional AU$250,000 sub-tranche under Tranche 2 of the facility. The latest drawdown relates to Sub-Tranche 04 (ST04) and follows previous subscriptions totalling AU$750,000 under Tranche 2 earlier in 2026. The broader funding agreement provides for up to AU$20 million in 4.0% redeemable convertible notes, structured across four tranches of AU$5 million each. Management stated that proceeds from the latest subscription will support ordinary business activities as well as future development programs, projects and investment opportunities as they arise. The additional funding provides Osteopore with increased financial flexibility as it continues commercialising its portfolio of 3D-printed biomimetic and bioresorbable implants within the regenerative medicine sector.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au